RNS Number : 3987O
EKF Diagnostics Holdings PLC
14 May 2024
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Result of AGM and Voting Results

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The voting results of the AGM were as follows:

 

 

For

Against

Withheld

Resolution

Votes

%

Votes

%

Votes

1

 248,228,094

99.78%

 547,604

0.22%

 58,727,253

2

 306,929,202

99.99%

 17,611

0.01%

 556,138

3

 307,478,974

100.00%

 13,855

0.00%

 10,122

4

 242,675,522

97.55%

 6,098,796

2.45%

 58,728,633

5

 307,473,521

99.99%

 19,308

0.01%

 10,122

6

 307,471,021

99.99%

 21,808

0.01%

 10,122

7

 302,901,784

98.51%

 4,594,167

1.49%

 7,000

8

 307,478,340

99.99%

 16,355

0.01%

 8,256

9

 307,474,469

99.99%

 16,029

0.01%

 12,453

10*

 305,495,468

99.35%

 1,998,483

0.65%

 9,000

11*

 251,801,517

81.89%

 55,692,434

18.11%

 9,000

12*

 247,115,598

83.20%

 49,902,353

16.80%

 10,485,000

 

*Special Resolutions

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair / Stephen Young, CFO

 via Walbrook PR



Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Oliver Platts




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

ā—

Point-of-Care analysers in the key areas of Hematology and Diabetes

 

ā—

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQKQBDBBKDQPD